Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
Company to report third quarter 2026 financial results and host conference call at 8:30 a.m. ET
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced it will host a conference call on Monday, November 16, 2026, at 8:30 a.m. Eastern Time to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide® commercial update. The Company will also report its third quarter 2026 financial results that day.
| Webcast and Conference Call | |
| Date/Time: | Monday, November 16, 2026, at 8:30 AM ET |
| Webcast: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=vTAb1pUs |
| Dial-in: | U.S.: 833-862-0853 |
| International: 412-365-5147 | |
| Please dial in 15 minutes prior to the start time. | |
Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days.
About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS.
Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.
Investor Contact
CORE IR
IR@cerenome.com
Media gallery
